ARTICLE | Clinical News

Pralatrexate: Phase II started

July 28, 2008 7:00 AM UTC

Allos began an open-label, international Phase II trial to evaluate an initial IV dose of 190 mg/m 2 pralatrexate given on days 1 and 15 of a 4-week cycle in combination with vitamin B12 and folic aci...